Apatinib for patients with metastatic biliary tract carcinoma refractory to standard chemotherapy: results from an investigator-initiated, open-label, single-arm, exploratory phase II study

BACKGROUND: There is no standard therapy for metastatic biliary tract carcinoma (BTC) refractory to first-line chemotherapy. Apatinib, a VEGFR2 tyrosine kynase inhibitor, showed an activity against BTC xenografts in preclinical models. We conducted an exploratory study to evaluate the efficacy and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chenchen, Huang, Mingzhu, Geng, Qirong, Li, Wenhua, Chang, Jinjia, Tang, Wei, Guo, Weijian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411636/
https://www.ncbi.nlm.nih.gov/pubmed/34484431
http://dx.doi.org/10.1177/17588359211039047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411636/
https://www.ncbi.nlm.nih.gov/pubmed/34484431
http://dx.doi.org/10.1177/17588359211039047

Ejemplares similares